Pennsylvania-based Cephalon Inc., which has a manufacturing facility in Salt Lake City, has received U.S. Food and Drug Administration approval to market a sugar-free formulation of its Actiq drug.
The new product will be launched in the first half of 2006.
Actiq contains medication used to treat "breakthrough" cancer pain. It is a single-use lozenge, attached to a handle, which delivers the medicine.
Cephalon has about 2,300 employees worldwide.